Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Lung Neoplasms × Blood Specimen Collection × Clear all

Phase

Phase NA 23 Phase EARLY_PHASE1 1 Phase 4 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 4 Colorectal Neoplasms 3 Neoplasms 2 Multiple Myeloma 2 Melanoma 2 Leukemia, Myeloid, Acute 2 Carcinoma, Non-Small-Cell Lung 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Sarcoma, Myeloid 1 Sarcoma 1 Rhabdoid Tumor 1 Pyloric Stenosis, Hypertrophic 1 Prostatic Neoplasms 1 Polycythemia Vera 1 Papillomavirus Infections 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neuroectodermal Tumors, Primitive 1 Lymphoma 1 Lung Neoplasms 1 Leukemia 1 Kidney Neoplasms 1 Histiocytoma, Malignant Fibrous 1 High Grade Neuroendocrine Neoplasms 1 Hereditary Breast and Ovarian Cancer Syndrome 1 Glioblastoma 1 Cytomegalovirus Infections 1 Colonic Neoplasms 1

Interventions

Carboplatin 160 Cisplatin 98 Pemetrexed 89 Paclitaxel 89 Docetaxel 79 Gemcitabine 77 Radiotherapy 73 Erlotinib Hydrochloride 50 Bevacizumab 44 Etoposide 40 durvalumab 32 pembrolizumab 30 Magnetic Resonance Spectroscopy 25 Specimen Handling 23 Radiosurgery 23 Nivolumab 23 Gefitinib 23 Vinorelbine 21 Irinotecan 21 Topotecan 20 osimertinib 18 atezolizumab 16 Drug Therapy 16 Radiation 13 Neoadjuvant Therapy 13 Cetuximab 13 Surgical Procedures, Operative 12 Filgrastim 12 Celecoxib 12 Ipilimumab 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06620835 2025-07-29

OPTALK

Groupe Francais De Pneumo-Cancerologie

Phase 2 Recruiting

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡